Background: Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial. We explored treatment outcomes according to primary platinum resistance (PPR) versus secondary platinum resistance (SPR).
recurrent ovarian cancer [1] . Patients with platinum-resistant disease-traditionally defined as relapsing within 6 months after completion of last platinum regimen-have a poor prognosis, with an overall survival (OS) expectancy of ∼12 months with chemotherapy [2] . However, the significance of the timing when platinum resistance develops is unclear.
Results of the recent randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC) demonstrated a significant improvement in oncologic outcome with the addition of bevacizumab to single-agent chemotherapy [3, 4] . Bevacizumab-containing therapy was associated with significant improvements in progression-free survival [PFS (primary end point); hazard ratio (HR) 0.48; 95% confidence interval (CI) 0.38-0.60; P < 0.001], objective response rate (ORR; 27% with bevacizumab versus 12% with chemotherapy alone; P = 0.001) [3] , and the primary patient-reported outcomes (PROs) end point, defined as the proportion of patients achieving a ≥15% improvement in abdominal/gastrointestinal symptoms at week 8/9 (22% versus 9%, respectively; P = 0.002) [4] .
Using data from the AURELIA database, we carried out an exploratory analysis investigating the clinical impact of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) on treatment efficacy. Our aim was to determine whether different timeframes in which patients develop platinum resistance translate into different clinical as well as biological behavior. In contrast to platinum-free interval (PFI), which was one of the three stratification factors in the trial, the definition for platinum resistance in the present exploratory analyses also takes into account the fact that SPR patients have responded to at least one chemotherapy with a PFI of at least 6 months and acquired platinum resistance over time, whereas PPR patients had initial recurrence within 6 months after the end of first-line treatment. Consequently, the addition of targeted therapeutics might be more beneficial for one of these two subgroups.
materials and methods

patients and study design
The design and methods of the AURELIA trial have been published previously [3, 4] then randomized to receive the selected chemotherapy either alone or with bevacizumab 10 mg/kg every 2 weeks (or 15 mg/kg q3w in patients receiving topotecan in the q3w schedule). Stratification factors were: selected chemotherapy (PLD versus paclitaxel versus topotecan), prior anti-angiogenic therapy (yes versus no), and PFI (<3 versus 3-6 months from last platinum therapy to subsequent progression). Chemotherapy and bevacizumab were continued until disease progression, unacceptable toxicity, or consent withdrawal. If significant toxicity necessitated discontinuation of one agent in the bevacizumab-containing arm, the remaining agent could be continued as monotherapy. Patients randomized to chemotherapy alone could cross over to receive single-agent bevacizumab 15 mg/kg q3w on clear evidence of progression after careful individual riskbenefit assessment by the investigator. The study was approved by national and/or participating-institution independent ethics committees.
definition of platinum resistance
In this substudy, platinum resistance was classified further according to response to previous anticancer treatments. PPR was defined as progression <6 months after completing first-line platinum-based chemotherapy (one or two chemotherapy regimens allowed). SPR was defined as progression ≥6 months after completing first-line platinum-based chemotherapy but <6 months after second-line platinum-based chemotherapy.
statistical analysis
All exploratory analyses were based on the intention-to-treat population. The Cox and logistic regression analyses were applied to correlate the time to development of platinum resistance with PFS, ORR, OS, and PROs. PFS and OS were calculated from the time of randomization to chemotherapy with or without bevacizumab. ORR was defined according to RECIST. The primary PRO end point in AURELIA was the proportion of patients achieving ≥15% improvement in abdominal/gastrointestinal symptoms (items 31-36 of the EORTC-QLQ-OV28 questionnaire) at week 8/9 [4] . Clinicopathological variables and treatment parameters were compared by applying an independent samples t-test or χ 2 test, as appropriate. Analyses in the current substudy were pre-specified before being carried out but were not defined until after publication of the primary results. There were no adjustments for multiple testing.
results
Of the 361 patients randomized in AURELIA, 262 (73%) were classified as PPR and 99 (27%) were classified as SPR. Within the PPR subgroup, 211 patients (58% of the entire study population) had received only one prior chemotherapy regimen and 51 (14%) had received two (and, in accordance with the PPR definition, had experienced disease progression <6 months after completing firstline treatment regimen) ( Figure 1 ). Baseline characteristics were similar in the two subgroups, except that a higher proportion of PPR than SPR patients had ascites at baseline (35% versus 21%, respectively; P = 0.01) ( Table 1 ). There were no significant differences between subgroups in the distribution of selected chemotherapy or crossover to bevacizumab at progression. In bevacizumab-treated patients (n = 179), SPR was associated with more favorable PFS than PPR [median 10.2 versus 5.6 months, respectively; HR 0.45 (95% CI 0.30-0.69); P < 0.001] (Figure 2 ). The same was observed for OS [median 22.2 versus 13.7 months, respectively; HR 0.46 (95% CI 0.30-0.70); P < 0.001]. There was a similar but non-significant trend in RECIST ORR among the 287 patients with measurable disease (38% versus 24% in the SPR and PPR subgroups, respectively; P = 0.094) which turned out to be significant when ORR was estimated by RECIST and/or GCIG criteria among the available 350 patients (44% versus 26%; P = 0.031).
Contrarily, in the chemotherapy-alone arm, differences between the SPR and PPR subgroups did not reach statistical significance for PFS or OS ( Figure 2 ). Similarly, there was no difference between SPR and PPR subgroups in RECIST ORR (16% versus 10%, respectively; P = 0.35). In multivariate analyses of the bevacizumab plus chemotherapy combination arm, SPR remained an independent prognostic factor for better PFS [adjusted HR 0.41 (95% CI 0.25-0.67), P < 0.001], as did ECOG performance status (P = 0.02) and PFI (P = 0.02; Table 2 , Bevacizumab plus chemotherapy arm). All three prognostic factors were also statistically significant in a separate multivariate analysis of OS (Table 2 , Bevacizumab plus chemotherapy arm). The OS HR for SPR versus PPR was 0.49 (95% CI 0.30-0.80; P = 0.005). In the chemotherapy-alone arm, the prognostic effect of PPR versus SPR did not reach statistical significance for either PFS or OS ( Table 2 , Chemotherapy-alone arm). However, the presence of ascites at baseline was prognostic for both PFS and OS, and ECOG performance status, CA-125, target lesion size, and PFI were all prognostic for OS ( Table 2 , Chemotherapy-alone arm).
PRO analyses indicated that the proportion of bevacizumabtreated patients achieving ≥15% improvement in abdominal/ gastrointestinal symptoms at week 8/9 was similar in the SPR and the PPR subgroups (22% versus 22%, respectively; P = 0.99). The only significant prognostic factor for PROs identified in multivariate analysis of bevacizumab-treated patients was ascites at baseline (odds ratio 0.13, 95% CI 0.05-0.35; P < 0.001). None of the explored factors was prognostic for PROs in multivariate analysis of the chemotherapy-alone arm.
Further analyses compared outcome according to randomized treatment within the SPR and PPR subgroups. The PFS benefit gained by adding bevacizumab to chemotherapy was numerically more pronounced in the SPR subgroup [HR 0.30 (95% CI 0.18-0.48); median 10.2 months with bevacizumab plus chemotherapy versus 3.7 months with chemotherapy alone] than in the PPR subgroup [HR 0.55 (95% CI 0.42-0.71); median 5.6 versus 2.8 months, respectively; treatment-subgroup interaction P = 0.07; Figure 3] . A similar non-significant direction of effect was observed for OS [SPR: HR 0.62 (95% CI 0.37-1.02), median 22.2 months with bevacizumab versus 15.6 months with chemotherapy alone; PPR: HR 0.94 (95% CI 0.71-1.24), median 13.7 versus 12.4 months, respectively; interaction P = 0.18; Figure 3] . Regarding response rate, in the SPR subgroup, the RECIST ORRs were 38% with bevacizumab versus 16% with chemotherapy alone, and in the PPR subgroup, the RECIST ORRs were 24% versus 10%, respectively. discussion Adding bevacizumab to standard single-agent chemotherapy represents an important advance in the treatment of PROC. This exploratory analysis of the AURELIA trial provides first evidence that prognosis, and perhaps also response to anti-angiogenic treatment, seems to vary according to the timeframe in which platinum resistance develops. In the group of patients treated with bevacizumab combined with chemotherapy, SPR patients (i.e. those with a PFI >6 months following initial platinum-based chemotherapy) had significantly longer PFS and OS compared with PPR patients, indicating a prognostic effect. This finding was supported by multivariate analysis of the bevacizumab-treated subgroup, in which SPR was identified as an independent prognostic factor for better PFS and OS. Conventionally, the definition of platinum resistance has focused solely on the interval between last platinum administration and diagnosis of recurrent disease, as proposed more than 20 years ago [5, 6] . However, our findings suggest that SPR ovarian cancer may be biologically different from PPR disease. For example, the median PFS for SPR patients treated with bevacizumab was 10.2 months (versus 5.6 months in PPR patients) and OS was almost doubled with a median of 22.2 months. This underlines both, the much better prognosis of SPR patients and the substantial benefit from bevacizumab in this population. It also challenges the classification of 'platinum-resistant' ovarian cancer, which may not adequately describe prognosis for the apparently heterogeneous population of patients with a PFI of <6 months following the most recent platinum-based therapy.
In contrast to PFS and OS, PROs did not differ according to the time to development of platinum resistance, nor was there any signal of variation in the magnitude of bevacizumab treatment effect on PROs. Bevacizumab improved gastrointestinal/ abdominal symptoms irrespective of the time to appearance of platinum resistance.
Concerning the magnitude of benefit from bevacizumab, the interaction test revealed borderline significance regarding differential treatment effect of bevacizumab according to SPR or PPR, but there was a numerical trend favoring the former subgroup. Initially, this seems counter-intuitive based on previous experience with bevacizumab as first-line therapy for ovarian cancer. Subgroup analyses have suggested that the benefit from bevacizumab might be greatest in patients with a worse prognosis (e.g. higher postoperative residual tumor load or more advanced stage disease) [7, 8] . However, in the present substudy, we observed a greater bevacizumab benefit in patients with a better prognosis.
Tumor burden characterized by tumor size, ascites, and CA-125 levels seems to be a major limiting factor of chemotherapeutic activity in the control arm as shown in OS multivariate analysis. This context seems to be less important for patient prognosis when bevacizumab is added. Various preclinical studies have suggested that the marked activity from the combination of bevacizumab and chemotherapy might be related to vascular normalization and reduced vascular permeability, leading to enhanced, more homogeneous chemotherapy delivery and/or possibly due to synergistic anti-angiogenic activity [9, 10] . These observations further support the idea that to maximize the therapeutic effect of bevacizumab requires coadministration with an effective chemotherapy, which may be less likely in the PPR setting. In our substudy, slightly fewer patients in the PPR than the SPR subgroup received paclitaxel as their chemotherapy regimen. However, as there were no significant imbalances in the chemotherapy partner selected by the investigator between the SPR and PPR subgroups, this seems an unlikely single explanation for the apparent differences.
The only baseline characteristic that was found to be significantly different between the SPR and PPR subgroups was the presence of ascites at baseline, which was more common in the PPR subgroup. Ascites is a known prognostic factor in ovarian cancer [11] ; moreover, because VEGF has been linked to the development of ascites, it might be anticipated that the treatment effect of an anti-VEGF agent such as bevacizumab could be greatest in patients with ascites. Indeed, ascites has been proposed as a potential biomarker for bevacizumab [12] . However, if the imbalance between subgroups in the presence of ascites had influenced outcome, an exaggerated treatment effect of bevacizumab in the PPR subgroup would be expected, which is the reverse of what we observed.
The main limitation of our findings is the exploratory nature of the analyses. Although calculations were pre-specified before performing the analyses presented here, they were not a part of the primary analysis before unblinding. As assessment of time to onset of platinum resistance in relation to treatment outcome was not part of the initial study plan, patients were not stratified according to time to development of platinum resistance (PPR versus SPR), limiting the conclusions that can be drawn.
Another limitation is the lack of translational research to understand mechanisms behind resistance in the two distinct subgroups identified in our study. With recent advances in our understanding of the clinical characteristics and tumor biology, further factors merit consideration when classifying the clinical course of disease in these patients. In particular, data on genetic alterations in these tumors attract increasing attention. Combining specific clinical markers and genetic footprints to predict response to targeted treatment strategies will be an important element of future research and may lead to specific trials realizing individualized medicine in ovarian cancer patients. Unfortunately, systematic collection of biomaterial was not included in the AURELIA protocol and therefore, exploration of BRCA status, gene expression patterns, and other potential candidate biomarkers cannot be addressed in this patient cohort.
Despite the caveats associated with exploratory analyses and the fact that the PFS, ORR, and PRO benefits in AURELIA were seen globally, regardless of the rapidity of platinum resistance onset, the present results strongly suggest that patients with PPR and SPR have differing prognoses and may respond differently to anti-angiogenic therapy. We therefore recommend that platinum resistance ( primary versus secondary) will be incorporated as an additional stratification factor in future trials evaluating anti-angiogenic therapy for PROC.
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